- Home
- NSIT vs RYTM Comparison
NSIT vs RYTM Comparison
Compare NSIT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSIT
- RYTM
- Stock Information
- Founded
- NSIT 1988
- RYTM 2008
- Country
- NSIT United States
- RYTM United States
- Employees
- NSIT N/A
- RYTM N/A
- Industry
- NSIT EDP Services
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- NSIT Technology
- RYTM Health Care
- Exchange
- NSIT Nasdaq
- RYTM Nasdaq
- Market Cap
- NSIT 4.3B
- RYTM 4.3B
- IPO Year
- NSIT 1995
- RYTM 2017
- Fundamental
- Price
- NSIT $139.99
- RYTM $86.70
- Analyst Decision
- NSIT Buy
- RYTM Strong Buy
- Analyst Count
- NSIT 4
- RYTM 13
- Target Price
- NSIT $185.00
- RYTM $88.77
- AVG Volume (30 Days)
- NSIT 297.3K
- RYTM 972.0K
- Earning Date
- NSIT 07-31-2025
- RYTM 08-05-2025
- Dividend Yield
- NSIT N/A
- RYTM N/A
- EPS Growth
- NSIT N/A
- RYTM N/A
- EPS
- NSIT 5.12
- RYTM N/A
- Revenue
- NSIT $8,425,769,000.00
- RYTM $136,863,000.00
- Revenue This Year
- NSIT $3.19
- RYTM $37.56
- Revenue Next Year
- NSIT $4.72
- RYTM $74.99
- P/E Ratio
- NSIT $27.33
- RYTM N/A
- Revenue Growth
- NSIT N/A
- RYTM 48.88
- 52 Week Low
- NSIT $126.10
- RYTM $40.61
- 52 Week High
- NSIT $228.07
- RYTM $94.80
- Technical
- Relative Strength Index (RSI)
- NSIT 53.26
- RYTM 76.93
- Support Level
- NSIT $140.71
- RYTM $64.65
- Resistance Level
- NSIT $146.83
- RYTM $94.80
- Average True Range (ATR)
- NSIT 3.63
- RYTM 3.47
- MACD
- NSIT 0.59
- RYTM 2.75
- Stochastic Oscillator
- NSIT 56.82
- RYTM 76.18
About NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, governments, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital innovation, cloud/data center transformation, connected workforce, and supply chain optimization solutions and services.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.